CLL
Advertisement
Patients with ibrutinib dose reduction after an AE had longer treatment length and similar efficacy versus no dose reduction.
A study on patterns in patients with CLL found the RFC regimen appeared to be most effective for OS and response rates.
Patients with chronic lymphocytic leukemia experience more anxiety when receiving intravenous versus oral treatments.
Patients with CLL who relapsed after HSCT and then received venetoclax therapy achieved outcomes consistent with trial data.
Background aims: Efforts to safely and effectively treat acute myeloid leukemia (AML) by targeting a single ...
At more than three years of follow-up, most patients with chronic lymphocytic leukemia (CLL) who were treated with a ...
According to three-year follow-up data from the ASCEND trial, patients with relapsed/refractory chronic lymphocytic ...
Zanubrutinib Plus Venetoclax Well-Tolerated, Effective as First-Line Therapy for CLL/SLL With Del17p
Preliminary data from a nonrandomized arm of the SEQUOIA trial, presented at the 2021 Annual Meeting of the American ...
Although individuals older than 80 years make up more than 20% of cases of chronic lymphocytic leukemia (CLL), this ...
According to a study presented at the 2021 American Society of Hematology Annual Meeting, frontline treatment with ...
Preliminary data from a nonrandomized arm of the SEQUOIA trial, presented at the 2021 Annual Meeting of the American ...
Although individuals older than 80 years make up more than 20% of cases of chronic lymphocytic leukemia (CLL), this ...
At the 2021 American Society of Hematology (ASH) Annual Meeting, researchers presented long-term follow-up data from a ...
At the 2021 American Society of Hematology Annual Meeting and Exposition, Fabio Efficace, PhD, and a team of researchers ...
Time-limited treatment with bendamustine, rituximab, and venetoclax was associated with high rates of undetectable ...
Frontline treatment with ibrutinib in combination with venetoclax induced deep responses in patients with previously ...
Acalabrutinib monotherapy demonstrated a sustained benefit for treatment of relapsed/refractory chronic lymphocytic ...
An analysis aimed to discern baseline demographics, symptoms, and survival outcomes of Waldenström macroglobulinaemia ...
A phase II study presented at the 2021 Annual Meeting & Exposition of the American Society of Hematology, reported ...
An analysis of real-world data regarding the treatment of patients with chronic lymphocytic leukemia revealed that ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.